Drug Trial Radar · NCT05257408
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
381
Actual
Start
Jun 29, 2022
Primary completion
Mar 31, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Conditions
- Ovarian Neoplasm
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
Interventions
Relacorilant 150 mgDrug
Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.
Nab-paclitaxel 80 mg/m^2Drug
Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
Nab-paclitaxel 100 mg/m^2Drug
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 20 months
- Overall SurvivalTime frame: Up to 32 months
Locations
116 sites in 14 countries. Site status is shown where the registry gives one.
Site 318
Phoenix, Arizona
Site 277
Tucson, Arizona
Site 350
Irvine, California
Site 364
La Jolla, California
Site 150
Palo Alto, California
Site 278
San Francisco, California
Site 014
San Francisco, California
Site 316
Solvang, California
Site 032
Aurora, Colorado
Site 335
Miami Beach, Florida
Site 042
Weston, Florida
Site 009
Atlanta, Georgia
Site 272
Atlanta, Georgia
Site 372
Gainesville, Georgia
Site 291
Savannah, Georgia
Site 315
Evanston, Illinois
Site 314
Hinsdale, Illinois
Site 346
Urbana, Illinois
Site 339
Indianapolis, Indiana
Site 200
Overland Park, Kansas
Site 334
Overland Park, Kansas
Site 279
Louisville, Kentucky
Site 128
Boston, Massachusetts
Site 288
New Brunswick, New Jersey
Site 292
Albuquerque, New Mexico
Site 275
Flushing, New York
Site 298
Cincinnati, Ohio
Site 304
Cincinnati, Ohio
Site 280
Portland, Oregon
Site 317
Portland, Oregon
Site 049
Portland, Oregon
Site 337
Bethlehem, Pennsylvania
Site 127
Pittsburgh, Pennsylvania
Site 276
Rapid City, South Dakota
Site 368
Germantown, Tennessee
Site 281
Nashville, Tennessee
Site 229
Austin, Texas
Site 312
Bedford, Texas
Site 297
Fort Worth, Texas
Site 392
San Antonio, Texas
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.